Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_90d863c6ac1f6b17c8da3f59358e97ed |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70503 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 |
filingDate |
2019-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45e9d4fcfcff88caa5e51ff8b0157d13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01ebd25bcd434b964a9b66d675896d5a |
publicationDate |
2019-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2019200462-A1 |
titleOfInvention |
Methods of preventing or treating non-hematopoietic slamf7 positive and slamf7 negative cancers |
abstract |
A method for the prevention and/or treatment of a neoplastic disease comprising a solid tumor in a subject in need thereof, said method comprising administering an effective amount of a signal regulatory protein alpha (SIRPalpha)-cluster of differentiation 47 (CD47) checkpoint inhibitor or a composition comprising the inhibitor, and a pharmaceutically acceptable carrier, to a subject having solid tumor cells expressing signaling lymphocytic activation molecule family member 7 (SLAMF7) and CD47. |
priorityDate |
2018-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |